Close
Condition
Search result for "Solr search content"
Search Result for ""
Clinical Trial
S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Bre
This clinical trial aims to validate the results observed in I-SPY2 and will test if adding durvalumab to neoadjuvant chemotherapy can increase pCR rates, shift residual cancer burden to lower values and improve invasive breast cancer free survival in early-stage HRpositive MP2 cancers.
Cancer Genetics Program
Cancer Genetics Program
Cancer Treatments
Cancer Treatments
provider
Brian Fricke, MD Physical Medicine, Cancer Rehabilitation
Oct
30
Story
Promising compound kills range of hard-to-treat cancers
Ratna Vadlamudi, PhD, a professor of obstetrics and gynecology at the Mays Cancer Center, is researching compounds that can target cancer cells to stop their growth.
Condition
Uterine Cancer
Condition